ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients

Duguesnoy, RJ; Aj, Anderson; Pa, Tomasulo; Aster, RH

doi:10.1182/blood.v54.3.595.595

Cited by 101 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Platelet transfusions were considered ABO incompatible if blood group A and/or B was present in the platelet donor but not in the patient. ABO-compatible platelets included all the other ABO matches and mismatches (14).…”

Section: Definitionsmentioning

confidence: 99%

Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation

Marktel

Napolitano

Zino³

et al. 2010

Pediatric Transplantation

View full text Add to dashboard Cite

Immune-mediated refractoriness to platelet transfusion is a major problem in patients undergoing HSCT. In a cohort of 50 pediatric patients affected by beta thalassemia coming from Middle East countries, we experienced a high incidence of refractoriness because of anti-HLA antibodies during post-HSCT aplasia. In a risk factors analysis, factors predicting a negative transfusion outcome were presence of spleen and the number of anti-HLA antibodies. We adopted a policy to select platelet donors by avoiding HLA antigens against which the patient had specific antibodies. Transfusion of dedicated units resulted in 26% refractoriness compared to 74% to random units (p < 0.0001). When dedicated transfusions were used, the presence of spleen did not influence transfusion outcome. Analyzing transfusion outcome depending on the degree of HLA match and ABO compatibility, 76% successful transfusions were obtained with HLA-matched- ABO compatible followed by 67% in HLA-1mismatch- ABO compatible or HLA-matched- ABO incompatible and by 46% in HLA-1mismatch- ABO incompatible. In conclusion, we provide evidence that the selection of platelet donors according to patient characteristics, anti-HLA antibodies and ABO matching, is successful in reducing platelet refractoriness in heavily alloimmunized thalassemia patients undergoing transplantation.

show abstract

Section: Definitionsmentioning

confidence: 99%

Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation

Marktel

Napolitano

Zino³

et al. 2010

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…Filip and Aster [I71 reported 58% recovery in 22 patients receiving 41 transfusions of pooled unit PC. Duquesnoy et al [18] detailed some 376 transfusions of DFC platelet concentrate, in which donor-recipient pairs were HLA matched or selectively mismatched. Posttransfusion platelet recoveries ranged from 31-73%.…”

Section: Discussionmentioning

confidence: 99%

Continuous‐flow techniques for platelet concentrate collection: A step toward standardization and yield predictability

Hester

Kellogg²,

Mulzet³

et al. 1985

J of Clinical Apheresis

View full text Add to dashboard Cite

This study chronicles leukocyte- and erythrocyte-depleted platelet concentrate collection by a dual stage channel in which three variables: 1) donor peripheral blood platelet concentration, 2) total blood processed, and 3) collection volume were statistically correlated with platelet yield as determined by a multiple regression analysis of single variables. Platelet concentration in the final yield was related to donor precount and collection rate, and could be varied as indicated for individual applications. Total blood processed was established by procedure time, which in turn was defined by citrate-induced calcium changes in the donor. Reduction in peripheral blood platelet concentration averaged 24% for a mean platelet yield of 3.8 X 10(11). An average of 40% of transfused platelet concentrates were recovered in recipient peripheral blood 1 hr posttransfusion and were hemostatically effective, as determined by correction of bleeding time. Platelet yields and patient response were sustained during current collection procedures, verifying the principles described during the investigative period.

show abstract

“…We order our products by ABO type, expecting to see a higher PLT recovery after transfusion when ABOcompatible products are transfused. 8 We expect the Red Cross to target an 85% compliance rate for ABO requests. Figure 2 is a snapshot of a small subset of inventory displaying the information known on each product.…”

Section: Relationship With Suppliermentioning

confidence: 99%

A comprehensive program to minimize platelet outdating

et al. 2011

View full text Add to dashboard Cite

We have identified three elements of our transfusion service that can minimize outdate: a knowledgeable proactive staff dedicated to PLT management, a comprehensive computer-based transfusion history for each patient, and a strong two-way relationship with the primary product supplier. Through our comprehensive program, based on the principles of providing optimal patient care, we have minimized PLT outdating for more than 10 years.

show abstract

ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients

Cited by 101 publications

References 12 publications

Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation

Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation

Continuous‐flow techniques for platelet concentrate collection: A step toward standardization and yield predictability

A comprehensive program to minimize platelet outdating

Contact Info

Product

Resources

About